Transcriptomics

Dataset Information

0

A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials [RNA-seq]


ABSTRACT: A cell line was derived from a mammary carcinoma in the transgenic FVB/N-Tg(MMTV-ErbB2)NDL2-5Mul mouse. The line, referred to as “NDL(UCD)” is adapted to standard cell culture and can be transplanted into syngeneic FVB/N mice. The line maintains a stable phenotype over multiple in vitro passages and rounds of in vivo transplantation. The cell line exhibits high expression of ErbB2 and ErbB3 and signaling molecules downstream from ErbB2. The line was previously shown to be reactive to anti-immune checkpoint therapy with responses conducive to immunotherapy studies. Here, using both histology/immunophenotyping and gene expression/microarray analysis, we show that the syngeneic transplant tumors elicit an immune reaction in the adjacent stroma, with additional tumor infiltrating lymphocytes. We also show that this immune activating effect is greater in the syngeneic transplants than in the primary tumors arising in the native transgenic mouse. We further analyzed the PD-1 and PD-L-1 expression in the model and found PD-L1 expression in the tumors and in vitro. In conclusion these data document the validity and utility of this cell line for in vivo preclinical immunotherapy trials.

ORGANISM(S): Mus musculus

PROVIDER: GSE113379 | GEO | 2019/03/06

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2019-03-06 | GSE112723 | GEO
2019-12-03 | PXD011885 | Pride
2020-03-10 | GSE134273 | GEO
2018-12-13 | GSE111360 | GEO
| PRJNA450984 | ENA
2021-02-16 | GSE159344 | GEO
2020-04-16 | E-MTAB-7777 | biostudies-arrayexpress
| PRJNA448828 | ENA
2022-05-15 | GSE202879 | GEO
2023-12-01 | GSE248271 | GEO